To validate further our hypothesis, namely, that the anti-EGFR monotherapy should be optimized in a patient-specific manner, we analyzed changes in gene expression levels in response to cetuximab monotherapy (anti-EGFR) in patient-derived HNSCC tumors (GSE109756, GEO database). This evidence concerns the gene EGFR and head and neck squamous cell carcinoma.